ReviewClinical and experimental rheumatology
The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum.
Review in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.Annals of dermatology · 2024Review
- Article
- Ulcerative rash in a patient with anti-MDA5 antibody-associated clinically amyopathic dermatomyositis.Clinical rheumatology · 2023Article
- Clinical spectrum and outcomes of idiopathic inflammatory myopathies in South Africans.Frontiers in medicine · 2023Article
- Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.International journal of women's dermatology · 2021Review
- Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review.Journal of general internal medicine · 2021Review
- Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry.Arthritis care & research · 2020Article
- Ovoid palatal patch: a clue to anti-TIF1γ dermatomyositis.BMJ case reports · 2020Article
- Interstitial Lung Disease with Anti-melanoma Differentiation-associated Protein 5 Antibody: Rapidly Progressive Perilobular Opacity.Internal medicine (Tokyo, Japan) · 2019Article
- Toll-like receptor 4: A promising therapeutic target for pneumonia caused by Gram-negative bacteria.Journal of cellular and molecular medicine · 2019Review
- The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria.The British journal of dermatology · 2019Review
- MRI assessment of the thigh musculature in dermatomyositis and healthy subjects using diffusion tensor imaging, intravoxel incoherent motion and dynamic DTI.European radiology · 2018Article
- Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.Annals of translational medicine · 2017Review
- Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.Clinical rheumatology · 2016Article
- Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients.PloS one · 2016Article
- Survival analysis and risk factors for mortality in connective tissue disease-associated pneumomediastinum.Rheumatology international · 2014Article
- Amyopathic dermatomyositis: definitions, diagnosis, and management.Current rheumatology reports · 2014Review
- Paraneoplastic syndrome in Hawai'i: a case of dermatomyositis associated with endometrial cancer.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2014Article
- Diagnosis, pathogenesis and treatment of myositis: recent advances.Clinical and experimental immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The objective of this review is to summarise the published evidence that supports the existence of amyopathic dermatomyositis (ADM) and its clinical significance including risk for rapidly progressive, fatal interstitial lung disease (ILD) and possible risk for internal malignancy. By establishing such inherent risks, we hope to establish the importance of formally recognising ADM as a subset of dermatomyositis (DM). Population-based epidemiologic studies have suggested that amyopathic DM might account for 20% of the total population of dermatomyositis (DM) patients (1). Patients presenting with ADM have been reported by investigators of multiple nationalities to be at risk for rapidly progressive, potentially fatal ILD (2-5). In addition, a new autoantibody, anti-CADM-140, has been reported to be a risk factor for the development of interstitial lung disease in CADM patients (6-9). It has been argued that ADM patients may be at increased risk of developing internal malignancy compared to the general population, though its rate in comparison to classic DM (CDM) needs further study (1, 10-12). In our population, 41% of CADM patients were previously classified as LE or UCTD. We conclude that ADM is a real entity that makes up a significant portion of the DM disease. It is important to formally recognise amyopathic DM as a subset of DM as it carries increased risk of ILD and possibly malignancy. Without appropriate disease classification, the opportunity for ILD and malignancy screening may be missed.
Indexed as
Identifiers
23190767PMC3883437W162176908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.